0 CHECKOUT

Pulmonary Arterial Hypertension - Pipeline Review, H1 2015

  • ID: 3165001
  • March 2015
  • 181 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Actelion Ltd
  • Bial - Portela & Ca, S.A.
  • Eli Lilly and Company
  • Longevity Biotech, Inc
  • Nippon Shinyaku Co., Ltd.
  • Silence Therapeutics plc
  • MORE

Pulmonary Arterial Hypertension - Pipeline Review, H1 2015

Summary

This, ‘Pulmonary Arterial Hypertension - Pipeline Review, H1 2015’, provides an overview of the Pulmonary Arterial Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actelion Ltd
  • Bial - Portela & Ca, S.A.
  • Eli Lilly and Company
  • Longevity Biotech, Inc
  • Nippon Shinyaku Co., Ltd.
  • Silence Therapeutics plc
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Pulmonary Arterial Hypertension Overview
Therapeutics Development
Pipeline Products for Pulmonary Arterial Hypertension - Overview
Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis
Pulmonary Arterial Hypertension - Therapeutics under Development by Companies
Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes
Pulmonary Arterial Hypertension - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pulmonary Arterial Hypertension - Products under Development by Companies
Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
Actelion Ltd
APT Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Ascendis Pharma A/S
Bial - Portela & Ca, S.A.
Cardioxyl Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Celladon Corporation
Celsion Corporation
Corridor Pharmaceuticals Inc.
Cytokinetics, Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
HanAll Biopharma Co., Ltd.
Insmed Incorporated
Ironwood Pharmaceuticals, Inc.
Lacer, S.A.
Longevity Biotech, Inc
LTT Bio-Pharma Co., Ltd.
Mast Therapeutics, Inc.
Mezzion Pharma Co. Ltd.
miRagen Therapeutics, Inc.
Nippon Shinyaku Co., Ltd.
Novartis AG
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proteo, Inc.
Reata Pharmaceuticals, Inc.
Sagene Pharmaceuticals, Inc.
Silence Therapeutics plc
Sinoxa Pharma GmbH
Suda Ltd
Therametrics holding AG
Toray Industries, Inc.
United Therapeutics Corporation
Pulmonary Arterial Hypertension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(allopurinol + apocynin) - Drug Profile
(chlorthalidone + valsartan) - Drug Profile
ACP-009 - Drug Profile
Antibody for Cancer and PAH - Drug Profile
Antibody for Pulmonary Arterial Hypertension - Drug Profile
APT-102 - Drug Profile
bardoxolone methyl - Drug Profile
beraprost sodium nanoparticles SR - Drug Profile
beraprost sodium SR - Drug Profile
BIA-51058 - Drug Profile
bosentan CR - Drug Profile
CT-2009 - Drug Profile
DasKloster-1000-01 - Drug Profile
Elafin - Drug Profile
esuberaprost sodium - Drug Profile
fasudil - Drug Profile
GS-4997 - Drug Profile
imatinib mesylate - Drug Profile
IW-1973 - Drug Profile
LA-419 - Drug Profile
lisuride - Drug Profile
macitentan - Drug Profile
Mydicar - Drug Profile
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile
PB-1046 - Drug Profile
PB-1120 - Drug Profile
Peptide to Antagonize Urotensin-II Receptor for PAH - Drug Profile
PGC-VIP - Drug Profile
PK-10453 - Drug Profile
R-190 - Drug Profile
ralinepag - Drug Profile
RNAi Oligonucleotide to Inhibit miR-145 for PAH - Drug Profile
selegiline + PDE-5 Inhibitor - Drug Profile
selexipag - Drug Profile
Small Molecule for Pulmonary Arterial Hypertension - Drug Profile
Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia - Drug Profile
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile
Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension - Drug Profile
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile
sodium nitrite - Drug Profile
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
SUD-004 - Drug Profile
Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension - Drug Profile
tadalafil - Drug Profile
TPN-171 - Drug Profile
treprostinil diolamine - Drug Profile
TXA-127 - Drug Profile
udenafil - Drug Profile
Pulmonary Arterial Hypertension - Recent Pipeline Updates
Pulmonary Arterial Hypertension - Dormant Projects
Pulmonary Arterial Hypertension - Discontinued Products
Pulmonary Arterial Hypertension - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2015
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H1 2015
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Carolus Therapeutics, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Celladon Corporation, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Cytokinetics, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Lacer, S.A., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Longevity Biotech, Inc, H1 2015
Pulmonary Arterial Hypertension - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2015
Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H1 2015
Pulmonary Arterial Hypertension - Pipeline by PharmaIN Corporation, H1 2015
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Sagene Pharmaceuticals, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics plc, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Sinoxa Pharma GmbH, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Therametrics holding AG, H1 2015
Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H1 2015
Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Pulmonary Arterial Hypertension Therapeutics - Recent Pipeline Updates, H1 2015
Pulmonary Arterial Hypertension - Dormant Projects, H1 2015
Pulmonary Arterial Hypertension - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2015
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Actelion Ltd
APT Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Ascendis Pharma A/S
Bial - Portela & Ca, S.A.
Cardioxyl Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Celladon Corporation
Celsion Corporation
Corridor Pharmaceuticals Inc.
Cytokinetics, Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
HanAll Biopharma Co., Ltd.
Insmed Incorporated
Ironwood Pharmaceuticals, Inc.
Lacer, S.A.
Longevity Biotech, Inc
LTT Bio-Pharma Co., Ltd.
Mast Therapeutics, Inc.
Mezzion Pharma Co. Ltd.
miRagen Therapeutics, Inc.
Nippon Shinyaku Co., Ltd.
Novartis AG
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proteo, Inc.
Reata Pharmaceuticals, Inc.
Sagene Pharmaceuticals, Inc.
Silence Therapeutics plc
Sinoxa Pharma GmbH
Suda Ltd
Therametrics holding AG
Toray Industries, Inc.
United Therapeutics Corporation

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Cytori Therapeutics, Inc.
  • Pfizer Inc.
  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Novo Nordisk A/S
  • Lumedx